

Figure S1. Study flow chart.

LVEF: left ventricular ejection fraction; NYHA: New York Heart Association; SBP: systolic blood pressure; eGFR: estimated glomerular filtration rate; Ace-i: angiotensin converting enzyme inhibitors; ARBs: angiotensin receptor blockers; CrCl: Creatinine Clearance; K⁺: potassium.




Figure S2. Sacubitril Valsartan dosage at 6-month follow up.

Table S1. Multivariable regression stepwise analysis with changes in LAVi.

Changes in LAVi	Beta	Std. Err.	b	Std. Err.	P-value
Changes in LVEDV	-0.4292	0.1315	-0.4244	0.1300	0.0024
Changes in PALS	-0.3283	0.1290	-0.1259	0.0495	0.0153
Baseline LVEDD	-0.2361	0.1315	-0.0061	0.0034	0.0808

LVEDV: left ventricular end-diastolic volume; PALS: peak atrial longitudinal strain; LVEDD: left ventricular end-diastolic diameter In bold p value < 0.05.